Yescarta car-t is a immunotherapy from Kite Pharma. In January 2021, Granny Ye was 71 years old at that time. She developed non-concave edema of the right lower limb without obvious inducement, accompanied by fatigue and night sweats. At that time, she only thought it was a minor disease. Unexpectedly, the result of her visit to the First Affiliated Hospital of Chongqing Medical University made her incredible. After completing the relevant examination and axillary lymph node puncture biopsy, Granny Ye was diagnosed as diffuse large B-cell lymphoma. The result was a bolt from the blue and totally unacceptable to her, her wife and three daughters.
In the subsequent treatment process, the hematology expert team made a complete plan for her. The patient went through 6 cycles of R-CHOP chemotherapy+2 cycles of R maintenance treatment. Ye’s focus gradually narrowed and achieved complete remission for a short time. However, in November 2021, recurrence occurred. Moreover, the progress was rapid, and many traditional therapies were unable to control the disease. In view of this, Professor Liu Lin and Professor Tang Xiaoqiong are the director of hematology department. They led the team to carry out analysis, research and judgment, comprehensively consider the patient’s condition, and CAR-T cell therapy .
In January 2022, Granny Ye and her family fully understood CAR-T cell therapy. Then the expert team informed them of the other key information of CAR-T cell therapy. They decided to accept CAR-T therapy.
After obtaining the consent of the patients and their families, Professor Liu Lin and Professor Tang Xiaoqiong led the team to carefully formulate the CAR-T treatment plan after multiple rounds of discussion and full demonstration. On January 30, the treatment team collected lymphocytes for patients, prepared CAR-T cells, and performed bridging IMRT radiotherapy. Then The patients in the treatment group assessed meet the conditions for reinfusion. The team treat the patients with FC protocol for purging on February 22, and successfully reinfused CAR-T cells (Aquilense injection) on March 7. After the transfusion, the expert team dynamically monitored the changes of the patient’s condition, properly handled the relevant complications, and timely optimized and adjusted the treatment methods. Grandma Ye’s indicators improved rapidly. Until March 7 of this year, in the year that Granny Ye received CAR-T cell therapy, many evaluations showed CR status (complete remission).
Later, according to Professor Liu Lin, CAR-T cell therapy, as a new immunotherapy method, uses the body’s own immune system to carry out individualized treatment, bringing hope for curing lymphoma patients. Patients with diffuse large B-cell lymphoma achieved complete remission through CAR-T therapy, which is not only good news for patients, but also greatly enhanced the confidence of hematologists.”